Table 3 Treatment, complications and outcome
Total (n = 125) | Survivors (n = 97) | Non-survivors (n = 28) | P | |
|---|---|---|---|---|
Covid severity* | 0.001 | |||
Mild | 37.6% (47) | 48.5% (47) | 0.0% (0) | |
Moderate | 27.2% (34) | 35.0% (34) | 0.0% (0) | |
Severe | 35.2% (44) | 16.5% (16) | 100% (28) | |
Treatment | ||||
Oxygen therapy | 60.0% (75) | 50.5% (49) | 92.9% (26) | < 0.0001 |
Maximal flow (L/min) | 3.0 (2.0–6.0) | 3.0 (2.0–6.0) | 5.0 (2.5–15.0) | 0.018 |
Antibiotics use | 61.6% (77) | 57.7% (56) | 75.0% (21) | 0.074 |
Combination of antibiotics | 33.6% (42) | 29.9% (29) | 46.4% (13) | 0.082 |
Beta-lactamine | 54.4% (68) | 50.5% (49) | 67.9% (19) | 0.079 |
Macrolides | 37.6% (47) | 35.1% (34) | 46.4% (13) | 0.279 |
2nd line antibiotics | 17.6% (22) | 14.4% (14) | 28.6% (8) | 0.096 |
Steroids | 8.0% (10) | 8.2% (8) | 7.1% (2) | 1.000 |
Hydroxychloroquine | 16.8% (21) | 16.5% (16) | 17.9% (5) | 1.000 |
Neuroleptics | 4.8% (6) | 5.2% (5) | 3.6% (1) | 0.678 |
Complications | ||||
ARDS | 25.6% (32) | 6.2% (6) | 92.9% (26) | < 0.0001 |
Cardiac injury | 13.6% (17) | 9.3% (9) | 28.6% (8) | 0.024 |
ACKI | 16.8% (21) | 12.4% (12) | 32.1% (9) | 0.021 |
Bacterial superinfection | 14.4% (18) | 11.3% (11) | 25.0% (7) | 0.122 |
Behavioural disorder | 19.2% (24) | 21.6% (21) | 10.7% (3) | 0.278 |
Diabetic ketoacidosis | 2.4% (3) | 3.1% (3) | 0.0% (0) | 1.000 |
Seizure | 2.4% (3) | 2.1% (2) | 3.6% (1) | 0.536 |
Stroke | 2.4% (3) | 2.1% (2) | 3.6% (1) | 1.000 |
Outcome | Total (n=125) | Survivors (n=97) | Non-survivors (n=28) | |
Total mortality | 22.4% (28) | |||
Delay admission-death | 8.5 (3.7–16) | |||
Length of stay | 16 (11–19.7) | |||
Discharge home before end of follow-up | 40.2% (39) | |||